Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
- PMID: 9455502
- DOI: 10.1086/516284
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Similar articles
-
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.Clin Pharmacokinet. 1995 Feb;28(2):143-60. doi: 10.2165/00003088-199528020-00005. Clin Pharmacokinet. 1995. PMID: 7736689 Review.
-
Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.Drugs. 2006;66(1):1-14. doi: 10.2165/00003495-200666010-00001. Drugs. 2006. PMID: 16398565 Review.
-
How can we predict bacterial eradication?Int J Infect Dis. 2003 Mar;7 Suppl 1:S13-20. doi: 10.1016/s1201-9712(03)90066-x. Int J Infect Dis. 2003. PMID: 12839703 Review.
-
The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.Respir Med. 2001 Jun;95 Suppl A:S12-9; discussion S26-7. doi: 10.1016/s0954-6111(01)90023-x. Respir Med. 2001. PMID: 11419669 Review.
-
Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.Bioorg Med Chem. 2016 Dec 15;24(24):6390-6400. doi: 10.1016/j.bmc.2016.11.008. Epub 2016 Nov 9. Bioorg Med Chem. 2016. PMID: 27887963 Review.
Cited by
-
Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach.Vet Res. 2021 Feb 27;52(1):34. doi: 10.1186/s13567-021-00906-0. Vet Res. 2021. PMID: 33640030 Free PMC article.
-
Bacterial temporal dynamics enable optimal design of antibiotic treatment.PLoS Comput Biol. 2015 Apr 23;11(4):e1004201. doi: 10.1371/journal.pcbi.1004201. eCollection 2015 Apr. PLoS Comput Biol. 2015. PMID: 25905796 Free PMC article.
-
Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.Infect Chemother. 2016 Jun;48(2):81-90. doi: 10.3947/ic.2016.48.2.81. Epub 2016 Jun 30. Infect Chemother. 2016. PMID: 27433378 Free PMC article.
-
Serum concentrations of amoxicillin in neonates during continuous intravenous infusion.Eur J Clin Microbiol Infect Dis. 2016 Jun;35(6):1007-12. doi: 10.1007/s10096-016-2630-z. Epub 2016 Apr 2. Eur J Clin Microbiol Infect Dis. 2016. PMID: 27039340
-
The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.Front Microbiol. 2016 Mar 22;7:385. doi: 10.3389/fmicb.2016.00385. eCollection 2016. Front Microbiol. 2016. PMID: 27047487 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous